PT  - JOURNAL ARTICLE
AU  - EUNSUNG JUN
AU  - JAEYOON JUNG
AU  - SEONG-YUN JEONG
AU  - EUN KYUNG CHOI
AU  - MOON BO KIM
AU  - JI SUN LEE
AU  - SEUNG-MO HONG
AU  - HYANG SOOK SEOL
AU  - CHANGMO HWANG
AU  - ROBERT M. HOFFMAN
AU  - IN KYONG SHIM
AU  - SUHWAN CHANG
AU  - SONG CHEOL KIM
TI  - Surgical and Oncological Factors Affecting the Successful Engraftment of Patient-derived Xenografts in Pancreatic Ductal Adenocarcinoma
DP  - 2016 Feb 01
TA  - Anticancer Research
PG  - 517--521
VI  - 36
IP  - 2
4099  - http://ar.iiarjournals.org/content/36/2/517.short
4100  - http://ar.iiarjournals.org/content/36/2/517.full
SO  - Anticancer Res2016 Feb 01; 36
AB  - Background: To effectively use pancreatic cancer patient-derived xenograft (PDX) models in translational research, successful PDX engraftment of surgical specimens in immune-deficient mice is needed. Materials and Methods: A total of 102 patients underwent pancreatic cancer resection using various procedures. Tumor tissue from all patents was implanted subcutaneously into mice. Tumor engraftment and growth in mice were determined. Engraftment was tested for correlation with operation type, time, tumor size, and oncogene expression using immunohistoculture. Results: Multivariate analysis showed that a tumor size of more than 3.5 cm in the patient was a significant factor related to successful PDX engraftment. In contrast, there was no correlation of engraftment with surgical procedure, time needed to remove the specimen, tumor differentiation, lymph node metastasis, and protein expression of p53, Receptor tyrosine-protein kinase erbB-2 (CERBB2), or deleted in pancreatic carcinoma locus 4 (DPC4). Conclusion: A minimum tumor size in the patient is an important factor for successful tumor engraftment.